168 related articles for article (PubMed ID: 37980651)
1. STEAP3 is a prognostic biomarker that promotes glioma progression by regulating immune microenvironment and PI3K-AKT pathway.
Song Z; Zhao Z; Zhu S; Jin Q; Shi Y; Zhang S; Wang Z; Wang Y; Zhao Z
Cancer Biomark; 2023; 38(4):505-522. PubMed ID: 37980651
[TBL] [Abstract][Full Text] [Related]
2. High expression of six-transmembrane epithelial antigen of prostate 3 promotes the migration and invasion and predicts unfavorable prognosis in glioma.
Deng L; Zeng S; Yi Q; Song L
PeerJ; 2023; 11():e15136. PubMed ID: 37009153
[TBL] [Abstract][Full Text] [Related]
3. IQGAP3 promotes the progression of glioma as an immune and prognostic marker.
Gao X; Ge J; Gao X; Mei NA; Su Y; Shan S; Qian W; Guan J; Zhang Z; Wang L
Oncol Res; 2024; 32(4):659-678. PubMed ID: 38560572
[No Abstract] [Full Text] [Related]
4. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
5. Arylsulfatase D is a prognostic biomarker that promotes glioma cells progression through JAK2/STAT3 pathway and M2 macrophage infiltration.
Song Z; Zhao Z; Zhu S; Jin Q; Zhang S; Wang Z; Shen B; Wang Z; Zhao Z
Front Oncol; 2023; 13():1228426. PubMed ID: 37766864
[TBL] [Abstract][Full Text] [Related]
6. Spinster homolog 2 reduces malignancies of glioblastoma via PTEN/PI3K/AKT pathway.
Liang W; Liu M; Su Y; Wen Y; Wang L; Shan J; Zhao J; Xie K; Wang J
IUBMB Life; 2024 Mar; 76(3):140-160. PubMed ID: 37728571
[TBL] [Abstract][Full Text] [Related]
7. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
8. Six-transmembrane epithelial antigen of prostate 3 (STEAP3) is a potential prognostic biomarker in clear cell renal cell carcinoma that correlates with M2 macrophage infiltration and epithelial-mesenchymal.
Wei H; Li Z; Zhao Y; Zhu S; Wen S; Quan C
Cancer Rep (Hoboken); 2023 Aug; 6(8):e1824. PubMed ID: 37344930
[TBL] [Abstract][Full Text] [Related]
9. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
Front Neurol; 2022; 13():977180. PubMed ID: 36353126
[TBL] [Abstract][Full Text] [Related]
10. STEAP3 can predict the prognosis and shape the tumor microenvironment of clear cell renal cell carcinoma.
Wu J; Bi Q; Zheng X; Cao H; Hao C; Sun Z; Wang W
BMC Cancer; 2022 Nov; 22(1):1204. PubMed ID: 36424540
[TBL] [Abstract][Full Text] [Related]
11. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
[TBL] [Abstract][Full Text] [Related]
12. GDF15 expression in glioma is associated with malignant progression, immune microenvironment, and serves as a prognostic factor.
Guo L; Chen Y; Hu S; Gao L; Tang N; Liu R; Qin Y; Ren C; Du S
CNS Neurosci Ther; 2022 Jan; 28(1):158-171. PubMed ID: 34697897
[TBL] [Abstract][Full Text] [Related]
13. SP140 inhibitor suppressing TRIM22 expression regulates glioma progress through PI3K/AKT signaling pathway.
Li X; Li G; Li L; Gao B; Niu X; Wang Y; Wang Z
Brain Behav; 2024 Mar; 14(3):e3465. PubMed ID: 38468469
[TBL] [Abstract][Full Text] [Related]
14. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of RNA methylation-related alternative splicing gene signature for low-grade glioma to predict survival and immune landscapes.
Ma C; Bao Y; Xu J; Xiao B; Li H
J Cancer Res Clin Oncol; 2023 Jan; 149(1):47-62. PubMed ID: 36528831
[TBL] [Abstract][Full Text] [Related]
16. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
[TBL] [Abstract][Full Text] [Related]
17.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
18. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer.
Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P
J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521
[TBL] [Abstract][Full Text] [Related]
19. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
20. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma.
Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J
Front Immunol; 2023; 14():1220100. PubMed ID: 37662954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
